Literature DB >> 33234669

Multisystem Inflammatory Syndrome in Children: An International Survey.

Carles Bautista-Rodriguez1,2,3, Joan Sanchez-de-Toledo4,5,3, Bradley C Clark6,7, Jethro Herberg8,9, Fanny Bajolle10,11, Paula C Randanne4, Diana Salas-Mera12, Sandrine Foldvari1,2, Devyani Chowdhury13, Ricardo Munoz14, Francesco Bianco15, Yogen Singh16,17, Michael Levin8,9, Damien Bonnet10,11, Alain Fraisse18,2.   

Abstract

OBJECTIVES: To describe presentation, hospital course, and predictors of bad outcome in multisystem inflammatory syndrome in children (MIS-C).
METHODS: Retrospective data review of a case series of children meeting the published definition for MIS-C who were discharged or died between March 1, 2020, and June 15, 2020, from 33 participating European, Asian, and American hospitals. Data were collected through a Web-based survey and included clinical, laboratory, electrocardiographic, and echocardiographic findings and treatment management.
RESULTS: We included 183 patients with MIS-C: male sex, 109 (59.6%); mean age 7.0 ± 4.7 years; Black race, 56 (30.6%); obesity, 48 (26.2%). Overall, 114 of 183 (62.3%) had evidence of severe acute respiratory syndrome coronavirus 2 infection. All presented with fever, 117 of 183 (63.9%) with gastrointestinal symptoms, and 79 of 183 (43.2%) with shock, which was associated with Black race, higher inflammation, and imaging abnormalities. Twenty-seven patients (14.7%) fulfilled criteria for Kawasaki disease. These patients were younger and had no shock and fewer gastrointestinal, cardiorespiratory, and neurologic symptoms. The remaining 77 patients (49.3%) had mainly fever and inflammation. Inotropic support, mechanical ventilation, and extracorporeal membrane oxygenation were indicated in 72 (39.3%), 43 (23.5%), and 4 (2.2%) patients, respectively. A shorter duration of symptoms before admission was found to be associated with poor patient outcome and for extracorporeal membrane oxygenation and/or death, with 72.3% (95% confidence interval: 0.56-0.90; P = .006) increased risk per day reduction and 63.3% (95% confidence interval: 0.47-0.82; P < .0001) increased risk per day reduction respectively.
CONCLUSIONS: In this case series, children with MIS-C presented with a wide clinical spectrum, including Kawasaki disease-like, life-threatening shock and milder forms with mainly fever and inflammation. A shorter duration of symptoms before admission was associated with a worse outcome.
Copyright © 2021 by the American Academy of Pediatrics.

Entities:  

Year:  2020        PMID: 33234669     DOI: 10.1542/peds.2020-024554

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  33 in total

1.  Recent research on the application of biologics in the treatment of multisystem inflammatory syndrome in children after SARS-CoV-2 infection.

Authors:  Han-Yu Cui; Chang-Ping Hu
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2022-02-15

2.  A Hybrid Protocol for Identifying Comorbidity-Based Potential Drugs for COVID-19 Using Biomedical Literature Mining, Network Analysis, and Deep Learning.

Authors:  Archana Prabahar; Anbumathi Palanisamy
Journal:  Methods Mol Biol       Date:  2022

3.  Which Findings Make multisystem Inflammatory Syndrome in Children Different from the Pre-Pandemic Kawasaki Disease?

Authors:  Ela Cem; Elif Böncüoğlu; Elif Kıymet; Şahika Şahinkaya; Miray Yılmaz Çelebi; Mustafa Gülderen; Pelin Kaçar; Aybüke Akaslan Kara; Ayşenur Aydın; Mehmet Murat; Murat Muhtar Yılmazer; Nuri Bayram; İlker Devrim
Journal:  Pediatr Cardiol       Date:  2022-07-08       Impact factor: 1.838

4.  Case Report: Lower Limb Muscle Weakness in a Child With Kawasaki Disease.

Authors:  Lilin Huang; Shumei Peng; Jing Li; Danyu Xie
Journal:  Front Pediatr       Date:  2022-06-21       Impact factor: 3.569

Review 5.  SARS-CoV-2-related MIS-C: A key to the viral and genetic causes of Kawasaki disease?

Authors:  Vanessa Sancho-Shimizu; Petter Brodin; Aurélie Cobat; Catherine M Biggs; Julie Toubiana; Carrie L Lucas; Sarah E Henrickson; Alexandre Belot; Stuart G Tangye; Joshua D Milner; Michael Levin; Laurent Abel; Dusan Bogunovic; Jean-Laurent Casanova; Shen-Ying Zhang
Journal:  J Exp Med       Date:  2021-06-07       Impact factor: 14.307

Review 6.  Multisystem inflammatory syndrome in children during the coronavirus disease pandemic of 2019: a review of clinical features and acute phase management.

Authors:  Naohiro Shioji; Kazuyoshi Aoyama; Marina Englesakis; Gail Annich; Jason T Maynes
Journal:  J Anesth       Date:  2021-05-30       Impact factor: 2.078

7.  Improving clinical paediatric research and learning from COVID-19: recommendations by the Conect4Children expert advice group.

Authors:  Athimalaipet V Ramanan; Neena Modi; Saskia N de Wildt
Journal:  Pediatr Res       Date:  2021-06-07       Impact factor: 3.953

8.  COVID-19 Infection in Spinal Muscular Atrophy Associated with Multisystem Inflammatory Syndrome.

Authors:  Rafat Mosalli; Amirah Al Matrafi; Mohammed A Ghazi; Gamal A Aboumousatafa; Bosco Paes
Journal:  Case Rep Pediatr       Date:  2021-06-30

9.  Multisystem Inflammatory Syndrome in Children: Unique Disease or Part of the Kawasaki Disease Spectrum?

Authors:  Caterina Matucci-Cerinic; Roberta Caorsi; Alessandro Consolaro; Silvia Rosina; Adele Civino; Angelo Ravelli
Journal:  Front Pediatr       Date:  2021-06-04       Impact factor: 3.418

10.  Cardiac echocardiogram findings of severe acute respiratory syndrome coronavirus-2-associated multi-system inflammatory syndrome in children.

Authors:  Ashraf S Harahsheh; Anita Krishnan; Roberta L DeBiasi; Laura J Olivieri; Christopher Spurney; Mary T Donofrio; Russell R Cross; Matthew P Sharron; Lowell H Frank; Charles I Berul; Adam Christopher; Niti Dham; Hemalatha Srinivasalu; Tova Ronis; Karen L Smith; Jaclyn N Kline; Kavita Parikh; David Wessel; James E Bost; Sarah Litt; Ashley Austin; Jing Zhang; Craig A Sable
Journal:  Cardiol Young       Date:  2021-08-05       Impact factor: 1.023

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.